Financings in Brief: Genzyme
This article was originally published in The Gray Sheet
Executive Summary
Genzyme: Offers $93 mil. in shares of Genzyme General Division common stock to acquire the assets of Genzyme Development Partners, L.P., also called the Surgical Aids Partnership. Genzyme established the Partnership in 1989 when it raised $36.8 mil. to fund development of surgical products to prevent postoperative adhesions. Premarket approval applications for the first of such products -- Seprafilm and Sepracoat -- are pending at FDA, and the company recently received the CE mark for Seprafilm. The stock offer "is in lieu of Genzyme's existing option," which stipulates that the surgical aids products business operate as a joint venture for two years following a product approval, after which Genzyme has an option to take over the partnership's interests in exchange for a $26 mil. lump-sum cash payment and 10% royalty payments for 10 years. The offer stipulates that shares be valued based on average closing price of Genzyme General Division stock "for the 20 trading days immediately preceding the fifth trading day prior to closing of the acquisition, provided that the average closing price is at least $60.99 and not more than $82.51," Genzyme says
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.